Loading clinical trials...
Loading clinical trials...
Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Associated Hyperammonemia With an Episode of Hepatic Encephalopathy (STOP-HE Study)
Conditions
Interventions
ornithine phenylacetate
placebo intravenous infusion
Locations
131
United States
Phoenix, Arizona, United States
Phoenix, Arizona, United States
Little Rock, Arkansas, United States
Coronado, California, United States
Los Angeles, California, United States
Los Angeles, California, United States
Start Date
January 7, 2014
Primary Completion Date
December 29, 2016
Completion Date
December 29, 2016
Last Updated
September 16, 2021
NCT06483737
NCT06052176
NCT04073290
NCT04014413
NCT06368895
NCT07437638
Lead Sponsor
Ocera Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions